Investors & Media

Nicholas Lydon, Ph.D., FRS, is a scientific founder of Blueprint Medicines and has served as a member of our Board of Directors since April 2011. Dr. Lydon is a Co-Founder of IDRx, Inc., and he is a Co-Founder of Recludix Pharma Inc. and has served on its Board of Directors and as a scientific advisor since 2019. Dr. Lydon serves as Managing Member of VB Therapeutics LLC, which he co-founded in 2019. In addition, Dr. Lydon currently serves as Managing Member of Staurus Biopharma, LLC, a privately held biopharmaceutical company that he co-founded. Dr. Lydon is a co-founder of AnaptysBio Inc. and served as a scientific advisor and member of its Board of Directors between 2006 and 2019. From 2003 to 2011, Dr. Lydon served as a scientific advisor and member of the Board of Directors of Ambit Biosciences Corp., a biopharmaceutical company focused on kinase inhibitor therapeutics. From 2000 to 2002, Dr. Lydon served as Vice President, Small Molecule Drug Discovery at Amgen, Inc. Prior to joining Amgen, Dr. Lydon founded and served as Chief Executive Officer of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors, which was acquired by Amgen in 2000. Prior to Kinetix Pharmaceuticals, Dr. Lydon worked for Ciba-Giegy AG (now Novartis AG), where he was responsible for the tyrosine protein kinase program, including the discovery and preclinical development of imatinib. Dr. Lydon has been awarded the Lasker-DeBakey Clinical Medical Research Award, the Kettering Prize from the General Motors Cancer Research Foundation and the Japan Prize for his role in the development of imatinib. Dr. Lydon received a B.S. in biochemistry and zoology from the University of Leeds, England, and received a Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.